AstraZeneca Launches New Real-World Evidence Study for Evushield COVID-19 Therapeutic in Abu Dhabi

AstraZeneca has announced the launch of a real-world evidence (RWE) study to investigate the safety and efficacy of Evushield, its COVID-19 treatment. Evushield is an antibody combination with an extended duration that is intended to help immunocompromised patients avoid symptomatic COVID-19. The project, entitled the “EVOLVE Real World Evidence Study,” will include 1,000 participants and will run through 2023.

According to Zawya, “bu Dhabi was among the first group of cities to receive the first global shipment of AstraZeneca’s Evusheld, long-acting antibody medication, to ensure the continuity of world-class care in the country. The multi-country, prospective observational study will support high-risk individuals across the United Arab Emirates and broader Middle East & Africa region by building a body of evidence on how Evusheld may protect against the COVID-19 virus.”

To read more, click here.

(Source: Zawya, August 29^th, 2022)